MedTrace Logo

Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

NCT05605470 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-04-13

No results posted yet for this study

Summary

This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous booster dose of any authorized/approved COVID-19 vaccine.

Conditions

  • COVID-19, SARS CoV 2 Infection

Interventions

BIOLOGICAL

ChulaCov19 BNA159 vaccine (50 mcg)

Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1

BIOLOGICAL

Pfizer/BNT vaccine (30 mcg)

Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1

BIOLOGICAL

COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)

Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1

Sponsors & Collaborators

  • Chulalongkorn University

    collaborator OTHER

  • BioNet-Asia

    collaborator UNKNOWN

  • Southern Star Research

    collaborator INDUSTRY

  • Technovalia, Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Kiat Ruxrunghtam, MD · Chulalongkorn University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-19
Primary Completion
2024-07-15
Completion
2024-11-18

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05605470 on ClinicalTrials.gov